These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation. Yi Qian ; Jing Pan ; Xiaodong Zhou ; Hourcade DE; Liszewski MK; Atkinson JP; Hong Lu ; Lijuan Zhang Clin Appl Thromb Hemost; 2010 Jun; 16(3):244-50. PubMed ID: 20547553 [TBL] [Abstract][Full Text] [Related]
26. Contaminated heparin associated with adverse clinical events and activation of the contact system. Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646 [TBL] [Abstract][Full Text] [Related]
27. [Hypersensitivity reaction and Chinese heparin]. Désormeaux A; Montpas N; Adam A Ann Pharm Fr; 2009 May; 67(3):169-72. PubMed ID: 19446665 [TBL] [Abstract][Full Text] [Related]
28. From crisis to opportunity: a perspective on the heparin crisis. Sasisekharan R; Shriver Z Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519 [No Abstract] [Full Text] [Related]
29. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products. Bairstow S; McKee J; Nordhaus M; Johnson R Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093 [TBL] [Abstract][Full Text] [Related]
30. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [TBL] [Abstract][Full Text] [Related]
34. Orthogonal analytical approaches to detect potential contaminants in heparin. Guerrini M; Zhang Z; Shriver Z; Naggi A; Masuko S; Langer R; Casu B; Linhardt RJ; Torri G; Sasisekharan R Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16956-61. PubMed ID: 19805108 [TBL] [Abstract][Full Text] [Related]
35. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins]. Delsart D; Chambefort V; Decousus H Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082 [No Abstract] [Full Text] [Related]
36. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method. Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048 [TBL] [Abstract][Full Text] [Related]
37. Heparin crisis 2008: a tipping point for increased FDA enforcement in the pharma sector? Rosania L Food Drug Law J; 2010; 65(3):489-501, ii. PubMed ID: 24479237 [TBL] [Abstract][Full Text] [Related]
38. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Levi M; Hovingh K Thromb Haemost; 2008 Dec; 100(6):1047-51. PubMed ID: 19132229 [No Abstract] [Full Text] [Related]